Brain tumors and plasmin inhibitors

Area of Science:

• Neuro-oncology
• Hematology
• Biochemistry

Background:

• Intracranial neoplasms are associated with thromboembolic complications.
• The role of fibrinolysis in the context of brain tumors is not well understood.

Observation:

• Four different intracranial neoplasms demonstrated in vitro inhibition of purified plasmin.
• Extracts from a parasagittal meningioma causing sinus occlusion showed 80% plasmin inhibition.
• Glioma extracts from a patient with multiple thromboembolic episodes exhibited >40% inhibition.

Findings:

• This study is the first to demonstrate plasmin inhibition activity associated with brain tumors.
• Tumor extracts exhibited varying degrees of plasmin inhibition, correlating with clinical thromboembolic events.
• Lesser inhibition (<30%) was observed in tumors from patients without thromboembolic complications.

Implications:

• Intracranial tumors may produce plasmin inhibitors to evade host antitumor fibrinolytic activity.
• Plasmin inhibitors produced by brain tumors could contribute to observed thromboembolic complications.
• Further research is needed to validate the role of plasmin inhibitors in brain tumor pathogenesis and associated complications.